- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CellaVision AB (CEVI)
CellaVision AB stock price live, this page displays ST CEVI stock exchange data. View the CEVI premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the CellaVision AB real time stock price chart below.
What Is the CellaVision AB Stock Price Today?
The CellaVision AB stock price today is 155.00.
What Is the Stock Symbol for CellaVision AB?
The stock symbol for CellaVision AB is "CEVI."
What Stock Exchange Does CellaVision AB Trade On?
CellaVision AB is listed and trades on the Stockholm stock exchange.
Is CellaVision AB a Good Stock to Buy?
Determining whether CellaVision AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CEVI quote. (ISIN: SE0000683484)
What Is the CellaVision AB Stock Price Today?
The CellaVision AB stock price today is 155.00.
What Is the Stock Symbol for CellaVision AB?
The stock symbol for CellaVision AB is "CEVI."
What Stock Exchange Does CellaVision AB Trade On?
CellaVision AB is listed and trades on the Stockholm stock exchange.
Is CellaVision AB a Good Stock to Buy?
Determining whether CellaVision AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CEVI quote. (ISIN: SE0000683484)
155.00
-0.60(-0.39%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
153.80
156.80
52 wk Range
147.80
232.50
CEVI is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
153.80156.80
52 wk Range
147.80232.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.61%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.61%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CEVI Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
228.75
Upside
+47.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
CellaVision AB Company Profile
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company’s CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas is an app with morphology experts for series mini lectures on extensive cell image library introduction to cell morphology; CellaVision Remote Review Software removes restrictive geographical constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
CellaVision AB Earnings Call Summary for Q3/2025
- CellaVision AB reported Q3 2025 net sales of CHF 176 million, down 1.7% YoY and missing forecasts of CHF 180.93 million, triggering a 10.23% stock price drop to 158.
- Despite revenue decline, the company achieved 2.6% organic sales growth after FX adjustments, with improved EBITDA of CHF 50 million (28% margin) and gross margin of 69%.
- Operating expenses rose to CHF 82 million with significant R&D investments, as CEO Simon Ostergard emphasized the company's innovation-focused strategy.
- Forward guidance includes CE Mark expectations for bone marrow application in Q1 2026 and US reagent market launch mid-2026, maintaining R&D investment levels.
- Challenges include revenue shortfall, increased expenses potentially pressuring profitability, and temporary softness in smaller instrument sales affecting short-term growth.
Last Updated: 2025-11-06, 06:16 a/m
Read Full TranscriptCompare CEVI to Peers and Sector
Metrics to compare | CEVI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCEVIPeersSector | |
|---|---|---|---|---|
P/E Ratio | 24.4x | 19.5x | −0.6x | |
PEG Ratio | 30.77 | −0.81 | 0.00 | |
Price/Book | 4.3x | 2.3x | 2.6x | |
Price / LTM Sales | 4.9x | 3.0x | 3.2x | |
Upside (Analyst Target) | 50.0% | 14.1% | 42.3% | |
Fair Value Upside | Unlock | 9.2% | 5.7% | Unlock |
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 228.75
(+47.58% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
1.31 / 1.42
Revenue / Forecast
175.62M / 180.93M
People Also Watch
FAQ
What Is the CellaVision AB (CEVI) Stock Price Today?
The CellaVision AB stock price today is 155.00
What Stock Exchange Does CellaVision AB Trade On?
CellaVision AB is listed and trades on the Stockholm Stock Exchange stock exchange.
What Is the Stock Symbol for CellaVision AB?
The stock symbol for CellaVision AB is "CEVI."
Does CellaVision AB Pay Dividends? What’s The Current Dividend Yield?
The CellaVision AB dividend yield is 1.61%.
What Is the CellaVision AB Market Cap?
As of today, CellaVision AB market cap is 3.70B.
What Is CellaVision AB's Earnings Per Share (TTM)?
The CellaVision AB EPS (TTM) is 6.35.
When Is the Next CellaVision AB Earnings Date?
CellaVision AB will release its next earnings report on Feb 05, 2026.
From a Technical Analysis Perspective, Is CEVI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has CellaVision AB Stock Split?
CellaVision AB has split 1 times.
How Many Employees Does CellaVision AB Have?
CellaVision AB has 231 employees.
What is the current trading status of CellaVision AB (CEVI)?
As of Dec 28, 2025, CellaVision AB (CEVI) is trading at a price of 155.00, with a previous close of 155.60. The stock has fluctuated within a day range of 153.80 to 156.80, while its 52-week range spans from 147.80 to 232.50.
What Is CellaVision AB (CEVI) Price Target According to Analysts?
The average 12-month price target for CellaVision AB is SEK228.75, with a high estimate of SEK240 and a low estimate of SEK210. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +47.58% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.